Pharmacologic Resistance in Colorectal Cancer: a Review

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2016 Jan 12

PMID 26753006

Citations 238

Authors

William A Hammond

Abhisek Swaika

Kabir Mody

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.

Citing Articles

Overexpression of miR‑424‑5p reduces cisplatin resistance by downregulating SMURF1 in gastric cancer.

Wang D, Cui H, Yan Y, Fu W, Lu L Oncol Lett. 2025; 29(3):143.

PMID: 39850720 PMC: 11755228. DOI: 10.3892/ol.2025.14889.

Correlations of the expression of Cx43, SCF, p-cyclin E1 (Ser73), p-cyclin E1 (Thr77) and p-cyclin E1 (Thr395) in colon cancer tissues.

Luan R, Liu M, Deng Z, Lu C, Yu M, Zhang M World J Gastrointest Oncol. 2025; 17(1):98410.

PMID: 39817129 PMC: 11664607. DOI: 10.4251/wjgo.v17.i1.98410.

PUF60 Promotes Chemoresistance Through Drug Efflux and Reducing Apoptosis in Gastric Cancer.

Liu Q, Song Y, Su J, Yang S, Lian Q, Wang T Int J Med Sci. 2025; 22(2):269-282.

PMID: 39781520 PMC: 11704696. DOI: 10.7150/ijms.102976.

Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective.

Kaviyarasan V, Das A, Deka D, Saha B, Banerjee A, Sharma N Int J Colorectal Dis. 2024; 40(1):1.

PMID: 39731596 PMC: 11682016. DOI: 10.1007/s00384-024-04790-w.

MiCK: a database of gut microbial genes linked with chemoresistance in cancer patients.

Shahzaib M, Muaz M, Zubair M, Kayani M Database (Oxford). 2024; 2024.

PMID: 39707929 PMC: 11662283. DOI: 10.1093/database/baae124.

References

Spano J, Fagard R, Soria J, Rixe O, Khayat D, Milano G . Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol. 2005; 16(2):189-94. DOI: 10.1093/annonc/mdi057. View

Lowenstein E, Daly R, Batzer A, Li W, Margolis B, Lammers R . The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell. 1992; 70(3):431-42. DOI: 10.1016/0092-8674(92)90167-b. View

Casanovas O, Hicklin D, Bergers G, Hanahan D . Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8(4):299-309. DOI: 10.1016/j.ccr.2005.09.005. View

Mitchell E . Targeted therapy for metastatic colorectal cancer: role of aflibercept. Clin Colorectal Cancer. 2012; 12(2):73-85. DOI: 10.1016/j.clcc.2012.08.001. View

Esposito C, Rachiglio A, La Porta M, Sacco A, Roma C, Iannaccone A . The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biol Ther. 2013; 14(12):1143-6. PMC: 3912037. DOI: 10.4161/cbt.26340. View

Xie H, Wood A, Kim R, Stein C, Wilkinson G . Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics. 2004; 5(3):243-72. DOI: 10.1517/phgs.5.3.243.29833. View

Wheeler J, Bodmer W, Mortensen N . DNA mismatch repair genes and colorectal cancer. Gut. 2000; 47(1):148-53. PMC: 1727951. DOI: 10.1136/gut.47.1.148. View

Jurgensmeier J, Schmoll H, ROBERTSON J, Brooks L, Taboada M, Morgan S . Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer. 2013; 108(6):1316-23. PMC: 3619270. DOI: 10.1038/bjc.2013.79. View

Kopetz S, Hoff P, Morris J, Wolff R, Eng C, Glover K . Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2009; 28(3):453-9. PMC: 2815707. DOI: 10.1200/JCO.2009.24.8252. View

10.

Shirota Y, Stoehlmacher J, Brabender J, Xiong Y, Uetake H, Danenberg K . ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001; 19(23):4298-304. DOI: 10.1200/JCO.2001.19.23.4298. View

11.

Marcuello E, Altes A, Menoyo A, Del Rio E, Baiget M . Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?. Cancer Chemother Pharmacol. 2005; 57(6):835-40. DOI: 10.1007/s00280-005-0089-1. View

12.

Zhang S, Lovejoy K, Shima J, Lagpacan L, Shu Y, Lapuk A . Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006; 66(17):8847-57. PMC: 2775093. DOI: 10.1158/0008-5472.CAN-06-0769. View

13.

Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G . Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol. 2007; 25(22):3238-45. DOI: 10.1200/JCO.2007.11.5956. View

14.

Van Emburgh B, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A . Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol. 2014; 8(6):1084-94. PMC: 5528615. DOI: 10.1016/j.molonc.2014.05.003. View

15.

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M . Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2012; 381(9863):303-12. DOI: 10.1016/S0140-6736(12)61900-X. View

16.

Bardelli A, Siena S . Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010; 28(7):1254-61. DOI: 10.1200/JCO.2009.24.6116. View

17.

Zhao J, Li W, Zhu D, Yu Q, Zhang Z, Sun M . Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Med Oncol. 2013; 31(1):802. PMC: 3890033. DOI: 10.1007/s12032-013-0802-6. View

18.

Tokunaga Y, Sasaki H, Saito T . Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine. Surgery. 2007; 141(3):346-53. DOI: 10.1016/j.surg.2006.06.025. View

19.

Holzer A, Manorek G, Howell S . Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol. 2006; 70(4):1390-4. DOI: 10.1124/mol.106.022624. View

20.

Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M . Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001; 19(21):4097-106. DOI: 10.1200/JCO.2001.19.21.4097. View